Rotavirus reassortant (ATCC® VR-2194)

Classification: Reoviridae, Rotavirus  /  Product Format: frozen

Classification Reoviridae, Rotavirus
Agent Rotavirus reassortant
Strain WI79-9, R573(4) [WI79-3.9]
Applications
vaccine production
Biosafety Level 2
Product Format frozen
Storage Conditions -70° or colder
Comments
Gene 9 is from strain WI79 from a human infant; other genes are from bovine rotavirus WC3.
This strain possesses neutralization antigen phenotype of both serotype 1 rotavirus and bovine (serotype 6) rotavirus.
Effect on Host
tumorigenicity: Cytopathic effects (clumping, crenation, and cell death)
Vague CPE appears as cell rounding and detachment within 7 to 10 days.
Recommended Host
MA-104 cells (ATCC CRL-2378); CV-1 cells (ATCC CCL-70); BS-C-1 cells (ATCC CCL-26); primary primate kidney cells

Host of Choice:  MA-104 (CRL-2378)

Host Range: MA-104, BSC-1, CV-1, primary primate kidney cells

Growth Conditions
Duration: 1-4 days at 37C
Effect on Host
tumorigenicity: Cytopathic effects (clumping, crenation, and cell death)
Vague CPE appears as cell rounding and detachment within 7 to 10 days.
Name of Depositor Wistar Institute
References

Clark HF, et al. Rotavirus reassortant vaccine. US Patent 5,626,851 dated May 6 1997

Wistar Institute, personal communication